In conclusion, considering both the pathophysiology of AD described above and the in vitro/ in vivo profiles of Compound A revealed in this study including activating AG/ANLS and enhancing pyruvate utilization, activating PDH through inhibiting PDHK by Compound A is expected to be a promising therapeutic strategy for AD. The gene discussed is PDP1; the disease is Alzheimer disease.